ScholarLens Back to search
2018•Journal of Thoracic OncologyOpen access

Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment

Ken Uchibori, Naohiko Inase, Makoto Nishio, Naoya Fujita, Ryohei Katayama

Open full text 30 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 30 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Osimertinib, Afatinib, Gefitinib, T790M, Resistance mutation, Mutation, Medicine, Erlotinib

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment — Research Paper | ScholarLens